Loading companies…

Bluechiip Ltd ASX:BCT

0 opened or increased0 held0 reduced or exitedlatest position by manager, past 12 months90 days: 0 increased, 0 reduced. 1 managers in total.

Position history by manager 1 managersSelect a point to see the comment

Opened or increasedHeldReduced or exited Start or end of the position not reported

20252026

30 Jun 2024 to today

Commentary Showing 2 of 3

DateManagerActionSummary

31 Dec 2024Saville CapitalHeldSaville Capital continues to hold Bluechiip Ltd because the company executed a licence, development and supply agreement with US-based BioLife Solutions — a market leader in bioproduction tools with a market cap of approximately USD $1.3 billion — granting BioLife exclusive rights to integrate Bluechiip's tracking technology into its primary packaging containers for the cell and gene therapy market. Saville Capital notes the agreement includes an upfront licence fee of USD $300,000 in year one and subsequent quarterly licence or royalty fees on BCT-enabled products, which the fund views as providing much-needed near-term revenue alongside longer-term significant royalty potential.

BiotechnologyMonthly Report

The source document link is a Pro feature

30 Sep 2024Saville CapitalHeldThe manager notes Bluechiip updated the market on its strategic review process, stating it remains engaged in detailed discussions with a number of international companies aimed at formalising proposals for its board to review in the coming weeks. In addition, the manager observes BCT announced the addition of another significant US customer with an initial contract executed during the month. The manager remains cautiously optimistic of a successful outcome to the strategic review, which should enable BCT to make a meaningful positive contribution to the Fund's performance.

BiotechnologyMonthly Report

The source document link is a Pro feature

1 more comments on BCTPro shows every comment, with a link to each source document.

Upgrade to Pro

First mention by manager

Price recorded at each manager's first comment

Price at first mentionThe share price recorded when each of 1 managers first commented on BCT.

View Pro

About Bluechiip Ltd

Healthcare, Software

Bluechiip (ASX:BCT), a developer of wireless tracking technology for biobanking, has pursued commercial partnerships. In December 2024, Saville Capital reported Bluechiip executed a licence, development and supply agreement with US-based BioLife Solutions, a Nasdaq-listed company. In September 2024, Saville noted Bluechiip remained engaged in detailed discussions with interested parties as part of its strategic review, and in June 2024 reported participating in a placement and shareholder loan raising around $700,000. Bluechiip operates in the Information Technology sector within the Software industry, and Thesis Tracker has captured 3 comments from 1 fund manager, Saville Capital. Headquartered in Melbourne, Bluechiip develops tracking solutions using MEMS sensor chips that operate at extreme temperatures, enabling accurate sample identification and temperature monitoring in cryogenic biobanks, laboratories and cell therapy storage.

Market cap: $4m
Price to earnings: Loss-making
Return on equity: 0.0%
Dividend yield: 0.0%
Price to book: 0.00x
Net margin: 0.0%

Company figures as of 15 Oct 2026. For information only.

Questions

Who is investing in Bluechiip Ltd (ASX:BCT)?

Fund managers including Saville Capital have invested in Bluechiip Ltd (ASX:BCT).

What opportunities or catalysts do fund managers highlight for Bluechiip Ltd?

Saville highlights the licence and supply agreement with BioLife Solutions, which could drive commercial adoption, and a strategic review exploring options.

What are the key risks to the Bluechiip Ltd investment thesis, according to fund managers?

Saville notes Bluechiip needed a small placement and shareholder loan to fund operations, highlighting funding risk.

What does Bluechiip Ltd (ASX:BCT) do?

Bluechiip Limited (ASX: BCT) develops and commercialises wireless tracking solutions for healthcare, life science, security, defence and manufacturing industries. Its technology is designed to replace current tracking methods, including handwritten and pre-printed labels, linear and 2D barcodes, and microelectronic IC-based RFID (Radio Frequency Identification).

General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.

11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.

Disclaimer Terms of Use Privacy Complaints Contact

Loading…